1,720,985 research outputs found
Depression in patients with medullary thyroid carcinoma
No full textCILJ ISTRAŽIVANJA:
Cilj ovog istraživanja je bio utvrditi postojanje i povezanost depresivnosti s
medularnim karcinomom štitnjače.
ISPITANICI I METODE:
Istraživanje je provedeno na Klinici za nuklearnu medicinu i Klinici za
endokrinologiju KBC-a Split. Uključivalo je one bolesnike koji su bili hospitalizirani pod
dijagnozom medularnog karcinoma štitnjače u razdoblju od 14 godina (2000. - 2014.). Podatci
su retrospektivno prikupljeni iz kartoteke povijesti, među ispitanicima je usmeno proveden
upitnik Beckov inventar depresije, te je sve obrađeno u programu Microsoft Office Excel
2007.
REZULTATI:
U razdoblju od 14 godina (2000. - 2014.) analizirano je 38 od 41 bolesnika, a od toga 26
žena i 12 muškaraca. Među bolesnicima je bilo 13 onih kojima je bolest otkrivena u dobi
između 40 i 50 godina, 11 kojima je bolest otkrivena u dobi između 50 i 60 godina, 7 kojima
je bolest otkrivena u dobi između 60 i 70 godina, te 3 bolesnika kojima je bolest otkrivena u
dobi manje od 40 godina. Veći broj bolesnika je bio iz prigradskih područja (n=21) nego iz
grada (n=17). Prema obrazovanju veći broj bolesnika je imalo stupanj srednje stručne spreme
(n=24) nego stupanj visoke stručne spreme (n=14). Analizom je utvrđeno da je 10 muških
bolesnika, te 22 bolesnice imalo povišene vrijednosti kalcitonina preoperativno. Nakon
operativnog zahvata 24 od ukupnog broja bolesnika je imalo povišene vrijednosti kalcitonina
postoperativno. Nakon provedenog upitnika Beckov inventar depresije utvrđeno je da je
najveći broj bolesnika minimalno depresivan (n=22), zatim slijede umjereno depresivni (n=6),
teže depresivni (n=6) i blago depresivni (n=4). Postoji statistički značajna razlika u
odgovorima na upitnik s obzirom na dob otkrivanja bolesti (p=0,0001), te razlika među
odgovorima onih kojima je bolest dijagnosticirana prije i onih kojima je bolest
dijagnosticirana poslije 51. godine života (p=0,0066).
ZAKLJUČAK:
Medularni karcinom štitnjače se češće pojavljuje kod žena, i to u dobi između 40 i 50
godina. Ovim istraživanjem nije dokazana povezanost depresivnosti i medularnog karcinoma
štitnjače, jer je najveći broj bolesnika minimalno depresivan.OBJECTIVES:
The aim of this study was to determine the association of depression with medullary
carcinoma of the thyroid.
EXAMINEES AND METHODS:
The study was conducted at the Department of nuclear medicine and Department of
endocrinology, University hospital Split. It included all patients who were hospitalized under
the diagnosis of medullary thyroid carcinoma in a period of 14 years (2000 - 2014). Data were
retrospectively collected from the medical history files, Beck depression inventory was
verbally conducted among respondents, and all that was processed in Microsoft Office Excel
2007.
RESULTS:
In a period of 14 years (2000 - 2014) 38 of 41 patients were analyzed, of which 26 women and
12 men. Among them, there were 13 of those to whom the disease was detected between the
ages of 40 and 50, 11 where the disease was detected between the ages of 50 and 60 years, 7
where the disease was detected between the ages of 60 and 70 years, and 3 patients whose
disease discovered at the age less than 40 years. A larger number of patients was from
suburban areas (n = 21) than the city (n = 17). By education a higher number of patients had
secondary level of education (n = 24) than the level of a university degree (n = 14). The
analysis found that 10 of the respondents male and 22 female patients had elevated calcitonin
preoperatively. After surgery, 24 of the total number of patients had elevated calcitonin
postoperatively. After completing the questionnaire Beck Depression Inventory was found
that the largest number of minimally depressed patients (n = 22), followed by moderately
depressed (n = 6), the harder depressed (n = 6) and slightly depressed (n = 4). There was a
statistically significant difference in the responses to the questionnaire with respect to age
detection of disease (p = 0.0001), and the difference between the responses of those whose
disease was diagnosed before and those who have been diagnosed with the disease after 51
years of age (p = 0.0066).
CONCLUSION:
Medullary thyroid cancer occurs more often in women, and between the ages of 40 and 50
years. This research has not been proven correlation depression and medullary thyroid cancer,
since the majority of patients minimally depressed
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Compliance with osteoporosis therapy at Clinical Department for Endocrinology of University Hospital Split
Full text linkCilj istraživanja: Cilj ovog istraživanja je odrediti u kojoj mjeri se pacijenti koji su započeli liječenje osteoporoze u endokrinološkoj ordinaciji KBC Split pridržavaju terapijskih uputa i koliko dugo se nastavljaju liječiti.
Metode: Ovo retrospektivno istraživanje obuhvatilo je 320 ispitanika koji su liječeni zbog osteoporoze u endokrinološkoj ordinaciji KBC Split u razdoblju između 1. siječnja 2003. i 31. prosinca 2006. godine. Podaci su prikupljeni pretraživanjem arhive Klinike za unutarnje bolesti.
Rezultati: Među 320 ispitanika bilo je 315 žena (98,4%) i 5 muškaraca (1,6%). Srednja vrijednost životne dobi svih ispitanika je 63,6 godina. Čimbenici rizika analizirani u ovoj studiji su: dob, spol, uzimanje kortikosteroida, preuranjena menopauza, pušenje, indeks tjelesne mase i niska koštana gustoća. Suradljivih pacijenata nakon prve godine liječenja bilo je 29,38%, nakon druge godine liječenja 11,53%, a nakon treće godine 4,94%. Najmanji postotak dolazaka (13,3%) zabilježen je među najmlađom dobnom skupinom (od 40 do 49 godina). Među pacijentima koji su se javili na dogovorenu kontrolu nakon godine dana više je onih koji su koristili Fosamax nego Evistu (25,54% prema 20,93%).
Zaključak: Stupanj suradljivosti u bolesnika s osteoporozom u provedenom istraživanju je ispod zadovoljavajuće razine. Posljedice su smanjena učinkovitost terapije te povećavan rizik za prijelome i viši troškovi liječenja.Objectives: To determine compliance with osteoporosis treatments and to evaluate factors influencing compliance.
Material and Methods: From January 2003 to December 2006 the medical history of 320 patients treated for osteoporosis were retrospectively reviewed. The data was gathered using hospital records from the Department's archives.
Results: In the current study period, the study included 320 patients treated for osteoporosis. Of the total number of patients, 315 were women (98,4%) and 5 men (1,6%) with the average age of 63,6. The risk factors for osteoporosis analyzed included the following: age, gender, corticosteroid use, age at menopause, BMI, smoking and lumbar and femoral BMD. One year after initiating treatment for osteoporosis only 29,38% of patients were compliant, compliance dropped to 11,53% at 2 year and 4,94% after 3 years. Younger people (40 to 49 years old) were found less likely to be compliant to the medication. Compliance was slightly higher in the Fosamax than in the Evista group (25,54% vs 20,93%).
Conclusion: Long-term compliance with osteoporosis therapy in this study was very poor. Poor compliance lead to diminished medication efficacy. These in turn lead to higher fracture rates and medical costs
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
SIDE-EFFECTS OF CHEMOTHERAPY IN HEMATOLOGICAL PATIENTS THE ROLE OF NURSE
No full textCilj: Provedeno istraživanje ima za cilj istražiti pojavnost nuspojava citostatske terapije u hematoloških bolesnika. Istraživanjem se želi utvrditi: koje su se nuspojave pojavile kod bolesnika koji su liječeni citostatskom terapijom; koje su najčešće nuspojave kod bolesnika koji su liječeni citostatskom terapijom; koje su najčešće nuspojave kod bolesnika koji su liječeni citostatskom terapijom s obzirom na pojedini protokol liječenja. Metode: Istraživanje je provedeno na slučajnom uzorku bolesnika na Zavodu za hematologiju KBC-a Split u razdoblju od siječnja do prosinca 2015. godine. Podatci za istraživanje su se dobili uvidom u medicinsku dokumentaciju i povijesti bolesti. Istraživanje je obuhvatilo ukupno 94 ispitanika. Prikupljeni podatci su uneseni u Microsoft Excel tablice prema unaprijed prikupljenom kodnom planu.
Rezultati: Najveći broj bolesnika koji su ušli u istraživanje se liječi pod dijagnozom non-Hodgkin limfoma (60%). Najzastupljenija dobna skupina je između 60-69 godina života. Niti jedan bolesnik nije bio mlađi od 18 godina niti stariji od 89 godina. Veća je bila zastupljenost ženskog spola (52,13%). Nuspojave koje su se javile nakon apliciranja citostatske terapije bile su: hematološke nuspojave, umor i slabost, mučnina i povraćanje, infekcije, opstipacija, kardiotoksičnost, gastrointestinalne nuspojave, sepsa, alergije, neuropatije, bolovi u trbuhu, akutno bubrežno zatajenje, oštećenje sluha, duboka venska tromboza, jetrena oštećenja, te upale sluznice. Najčešći kemoterapijski protokoli bili su: RCHOP, RCOP, RCNOP, COP i RFC. Za kemoterapijski protokol RCHOP pet najčešćih nuspojava su bile anemija, umor i slabost, neutropenija, mučnina i vrućica. Za kemoterapijski protokol RCOP to su bile anemija, umor i slabost, mučnina, vrućica te febrilna neutropenija. Za kemoterapijski protokol RCNOP najčešće nuspojave su anemija, umor i slabost, vrućica, neutropenija i ataksija. Za kemoterapijski protokol COP najčešće nuspojave su anemija, umor i slabost, vrućica, neutropenija i ataksija. Nuspojave koje su se javile kod protokola RFC su anemija, vrućica, mučnina, trombocitopenija te umor i slabost.
28
Zaključak: Kod hematoloških bolesnika koji su primili hematološku terapiju pojavile su se 24 nuspojave. Najčešća nuspojava bila je anemija. Najčešće primjenjeni kemoterapijski protokol bio je „RCHOP“, a nuspojava koja se najčešće pojavljivala po primjeni ovog protokola bila je anemija.Introduction and aim: This research aims to investigate the side effects of chemotherapy in hematologic patients. The research is to determine: what are the side effects occurred in patients treated with chemotherapy; which are most common side effects in patients treated with chemotherapy; which are the most common side effects in patients treated with chemotherapy with regard to a particular treatment protocol.
Material and methods: The study was conducted on a random sample of patients at the Department of Hematology KBC Split in period from January to December 2015. Data for the study were obtained by examining the medical records and medical history. The study included a total of 94 respondents. The data were entered into a Microsoft Excel spreadsheet to advance collected the code level.
Results: The majority of patients who entered the study treated with the diagnosis of non-Hodgkin's lymphoma (60%). The most common age group is between 60-69 years of life. No patients were younger than 18 or older than 89 years. The higher the representation of females (52.13%). Side effects that occurred after application of chemotherapy were: hematologic adverse reactions, fatigue and weakness, nausea and vomiting, infections, constipation, cardiotoxicity, gastrointestinal side effects, sepsis, allergies, neuropathy, abdominal pain, acute renal failure, hearing loss, profound venous thrombosis, liver damage and inflammation of the mucous membranes. The most common chemotherapy protocols were: RCHOP, RCOP, RCNOP, COP and RFC. For chemotherapy protocol RCHOP five most common side effects were anemia, fatigue and nausea, neutropenia, nausea and fever. For chemotherapy protocol RCOP it were anemia, fatigue, weakness, nausea, fever and febrile neutropenia. For chemotherapy protocol RCNOP most common side effects were anemia, fatigue and nausea, fever, neutropenia, and ataxia. For chemotherapy protocol COP most common side effects were anemia, fatigue and nausea, fever, neutropenia, and ataxia. Side effects that occurred with the protocol RFC anemia, fever, nausea, thrombocytopenia and fatigue and weakness.
30
Conclusion: In hematological patients receiving hematological therapy appeared 24 side effects. The most common side effect was anemia. The most commonly applied chemotherapy protocol was "RCHOP", a side effect that usually appeared after the implementation of this protocol was anemia
Health-related quality of life in women with osteoporosis treated with denosumab
No full textCilj: Cilj ovog istraživanja je utvrditi kvalitetu zdravlja oboljelih od osteoporoze liječenih denosumabom putem anketnog upitnika.
Ispitanici i postupci: U istraživanje je uključeno 50 pacijentica sa Zavoda za internu medicinu. Sve imaju dijagnozu osteoporoze te se liječe denosumabom. Podatci su prikupljeni pregledom medicinske dokumentacije i provedbom anketnog upitnika. Anketiranje ispitanica je provedeno telefonskim putem, jer zbog pandemije uzrokovane novim SARS-CoV-2 virusom nismo željeli izlagati pacijentice riziku razvoja infekcije.
Rezultati: Najveći broj ispitanica svoje je zdravlje subjektivno ocijenilo kao dobro (84%), dok je manji broj ocijenilo kao odlično (10%), a najmanji kao loše (6%). Ispitivanjem povezanosti između fizičke onesposobljenosti i potrebe za prilagođavanjem je utvrđeno postojanje pozitivne i statistički značajne povezanosti isto kao i od povezanosti između starosne dobi i potrebe za prilagođavanjem te straha i fizičke onesposobljenosti. Strah i potreba za prilagođavanjem nisu statistički značajno povezani. Pronađena je pozitivna povezanost između vrijednosti denzitometrijskog mjerenja lumbalne kralježnice i starosti. Ispitivanjem povezanosti između vrijednosti denzitometrijskog mjerenja femura i starosti, straha, fizičke sposobnosti, te prilagođavanja nije utvrđeno postojanje povezanosti. Veća je razina straha kod promatranih pacijenata koji nemaju komorbiditete u odnosu na razinu straha pacijenata koji imaju komorbiditete, dok ispitivanjem nije utvrđeno postojanje razlike. Fizička sposobnost veća je kod promatranih pacijenata koji nemaju komorbiditete u odnosu na pacijente koji imaju komorbiditete, dok ispitivanjem nije utvrđeno postojanje razlike. Razina prilagođavanja je veća kod promatranih pacijenata koji nemaju komorbiditete u odnosu na pacijente koji imaju komorbiditete, dok ispitivanjem nije utvrđeno postojanje razlike.
Zaključci: Nismo dokazali razliku u kvaliteti zdravlja kod ispitanica sa osteoporozom koje imaju komorbiditete u usporedbi sa ispitanicama koje iste nemaju.Objectives: The aim of this study was to determine health-related quality of life among patients with osteoporosis treated with denosumab through a questionnaire.
Subjects and methods: The study included 50 patients from the Department of Internal Medicine. They are all diagnosed with osteoporosis and are treated with denosumab. Data were collected by reviewing medical records and conducting a survey questionnaire. The respondents were interviewed by telephone, because due to the pandemic caused by the new SARS-CoV-2 virus, we did not want to expose the patient to the risk of developing an infection.
Results: The largest number of respondents subjectively rated their health as good (84%), while a smaller number rated it as excellent (10%), and the smallest as poor (6%). Examining the association between physical disability and the need for adjustment, the existence of a positive and statistically significant association was found, as well as the relationship between age and the need for adjustment, and fear and physical disability. Fear and the need for adjustment are not statistically significantly related. A positive correlation was found between the values of densitometric measurement of the lumbar spine and age. Examination of the association between the values of densitometric measurement of the femur and age, fear, physical ability, and adjustment did not establish the existence of an association. The level of fear was higher in the observed patients who did not have comorbidities compared to the level of fear in patients who had comorbidities, while the examination did not determine the existence of a difference. Physical capacity was higher in the observed patients who did not have comorbidities compared to patients who had comorbidities, while the examination did not establish the difference. The level of adjustment is higher in the observed patients who do not have comorbidities compared to the patients who have comorbidities, while the examination did not establish the existence of a difference.
Conclusions: We did not prove a difference in the quality of health in subjects with osteoporosis who have comorbidities compared to subjects who do not
The necessity of transfusional therapy in patients with myelodysplastic syndrome
Full text linkCilj istraživanja: Cilj istraživanja je bio utvrditi kvalitativne i kvantitativne potrebe za transfuzijskim liječenjem u bolesnika oboljelih od MDS-a s obzirom na parametre spola, dobi, MDS klasifikacije, godinu početne dijagnoze, trajanje bolesti, prosječne vrijednosti eritrocita, trombocita i hemoglobina, broj primljenih transfuzija eritrocita i trombocita za vrijeme hospitalizacije te broj smrtnih ishoda.
Metode: U ovom retrospektivnom istraživanju obuhvaćena su 63 bolesnika s ukupno 119 hospitalizacija na Zavodu za hematologiju Klinike za unutarnje bolesti KBC-a Split u razdoblju od 1. siječnja 2013. do 31. prosinca 2014. godine. Podaci su prikupljeni popisnom metodom iz arhive Klinike za unutarnje bolesti te Zavoda za transfuzijsku medicinu probirom otpusnih pisama te usporedbom s bolničkim kartonima.
Rezultati: Među 63 ispitanika je bilo 26 žena (41,27%) i 37 muškaraca (58,73%), prosječne životne dobi od 74 godine. Tijekom istraživanja je preminulo 13 ispitanika (20,63%), a udio smrtnih ishoda prevladava kod muškaraca (61,54% prema 38,46%). Najčešće dijagnosticirana podvrsta bolesti je MDS neklasificirani (32%), a najveći broj smrtnih ishoda se dogodio pod dijagnozom AML transformacije (38,5%). Najveći broj ispitanika je bio hospitaliziran samo jednom (61,9%). U 75,63% hospitalizacija su bile potrebne transfuzije eritrocita, a u 47,05% transfuzije trombocita. Prosječni broj primljenih eritrocitnih transfuzija kod žena iznosi 1,95 doza, a kod muškaraca 1,54 doze. Prosječni broj primljenih trombocitnih transfuzija iznosi 2,37 doza.
Zaključak: MDS je klinički heterogena bolest starije životne dobi koja zahtijeva višestruka bolnička liječenja, a češće pogađa muškarce. Liječenjem se nastoji spriječiti ili barem odgoditi pojava dvaju neminovnih ishoda – leukemijske transformacije i ovisnosti o transfuzijskom liječenju. Broj ispitanika je obrnuto proporcionalan broju hospitalizacija po ispitaniku. Razlog tome je postojanje dnevne bolnice kroz koju se većina bolesnika uspješno liječi, umanjujući potrebe za hospitalizacijom. Prosječni broj svih primljenih transfuzija se povećava s učestalošću bolničkog liječenja. U 3/4 hospitalizacija su bile potrebne transfuzije eritrocita, a u gotovo pola slučajeva transfuzije trombocita.Objectives: The aim of this study was to determine qualitative and quantitative demands of transfusional therapy in patients with myelodisplastic syndrome with regards to age, sex, MDS classification, year of initial diagnosis, duration of the disease, red and platelet count, haemoglobin levels, red and platelet count, number of administered RGB, platelet and fresh frozen plasma transfusions and finally the number of deceased patients
Methods: This retrospective study encompassed 63 individual patients (119 due to recurring hospitalizations) with MDS who were admitted and treated at the Department of Hematology, University Hospital Split in the period from January 1st 2013 to December 31st 2014. The data was gathered using hospital records from the Department's archives for case identification and cross-referencing them with data from the Departmen of Transfusion Medicine.
Results: The study encompassed 63 subjects consisting of 26 women (41,27%) and 37 men (58,73) with the average age of 74. During the research 13 subjects (20,63%) passed away with the ratio of mortality being more dominant in men (61,54% to 38,46%). The most diagnosed subgroup was MDS unclassified (32%) and the majority of deaths occured under the diagnosis of AML transformation (38,5%). The majority of subjects required only one hospitalization (61,9%). Erythrocyte and thrombocyte transfusions were required in 75,63% and 47,05% cases, respectively. The average number of administered erythrocyte transfusions for women and men was 1,95 and 1,54 doses, respectively. The average number of thrombocyte transfusions was 2,37 doses.
Conclusion: MSD is a clinically heterogenic disease of the elderly which requires multiple hospitalizations, occuring more often in men. The main goal of treatment is to prevent or to postpone the occurance of two inevitable outcomes – leukemic transformation and transfusion dependence. The number of patients is inversely proportional to the number of hospitalizations per subject with the main reason being the existance of the daily hospital through which the majority of patients is treated, diminishing the need for hospital admittance. The average number of all administered transfusions increases with the frequency of hospitalizations. 3/4 of cases required erythrocyte transfusions and nearly half of them required thrombocyte transfusions
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Molekularni odgovor na terapiju inhibitorima tirozin kinaze u bolesnika s Ph¹⁺ KML
No full textKML Ph¹⁺ nastaje zloćudnom preobrazbom pluripotentne krvotvorne matične stanice čijom autonomnom proliferacijom nastaje klon istovrsnih zloćudno promijenjenih stanica. U početku se razvija kao kronična faza s prosječnim trajanjem 3 - 4 godine, a potom prelazi u akutnu fazu, odnosno akutnu leukemiju. Od svih slučajeva malignih bolesti 3 % se odnosi na leukemije. KML Ph¹⁺ čini 20 % svih leukemija. Incidencija je oko 1 novi slučaj / 100 000 stanovnika godišnje. Danas je zbog vrlo učinkovite terapije prevalencija KML-a Ph¹⁺ u godišnjem porastu od 4,5.
Cilj ovog istraživanja je procjena molekularnog odgovora (velikog i kompletnog) u bolesnika s Ph¹⁺ KML. Utvrditi razliku i učinkovitost terapije u bolesnika koji se liječe sa prvom i drugom generacijom inhibitora tirozin kinaze.
Uzorak ispitanika definiran je ukupnim brojem bolesnika koji se liječe inhibitorima tirozin kinaze na Odjelu hematologije u KBC-u Split. Napravljena je retrospektivna studija u kojoj su korišteni podaci u periodu od 2004. do 2014 godine. Istraživanje je obuhvatilo 30 bolesnika od kojih je 18 muškog spola (60 %), a 12 ženskog spola (40%). Medijan životne dobi je 58 godina. Najstariji bolesnik je imao 88 godina kod postavljanja dijagnoze, najmlađi 23 godine.
Pri postavljanju dijagnoze 2 bolesnika su bila u ubrzanoj fazi bolesti (7 %), 28 bolesnika u kroničnoj fazi bolesti (93 %).
Rezultati analize za bolesnike koji se liječe u KBC-u Split su u skladu sa očekivanim terapijskim odgovorom. Slični su rezultatima kliničkih ispitivanja (ENESTcmr studije, IRIS studije i ENESTnd studije).
Zahvaljujući ovim ciljano molekularnim ljekovima život bolesnika s Ph¹⁺ KML koji postignu optimalan terapijski odgovor je sličan životu zdrave populacije iste životne dobi.
Danas bi cilj ove učinkovite terapije trebao biti postizanje dubokog molekularnog odgovora, jer se na takav način signifikantno smanjuje mogućnost neželjenih događaja: progresija u ubrzanu fazu/blastičnu fazu i pojava mutacija.CML Ph ¹ ⁺ formed malignant transformation of pluripotent hematopoietic stem cells whose autonomous proliferation occurs same malignant clone of altered cells. Initially developed as a chronic phase with an average duration of 3 - 4 years, and then at the acute phase or acute leukemia. All cases of malignancies, 3 % is related to leukemia. CML Ph ¹ ⁺ makes 20 % of all leukemia. The incidence is approximately one new case / 100 000 per year. Today is a very effective therapy for the prevalence of CML and Ph ¹ ⁺ in annual increments of 4.5. The aim of this study is to assess molecular response (major and complete) in patients with Ph ¹ ⁺ CML. Identify the difference and efficacy of therapy in patients treated with first and second generation tyrosine kinase inhibitors. The sample is defined by the total number of patients treated with tyrosine kinase inhibitors at the Department of Hematology at University Hospital in Split. Incorporating a retrospective study in which data were used in the period from 2004 to 2014 year. The study included 30 patients, of which 18 are male (60 %) and 12 females (40 %). The median age was 58 years. The oldest patient was 88 years at diagnosis, the youngest 23 years old. When diagnosing two patients were in accelerated phase disease (7 %), 28 patients in the chronic phase of the disease (93 %). Results of the analysis to patients who are being treated in hospital in Split are in line with the expected therapeutic response. They are similar to the results of clinical trials (Studies ENESTcmr, IRIS study and ENESTnd study). Thanks to these targeted molecular drugs life of patients with Ph ¹ ⁺ CML who achieve optimal therapeutic response is similar to the life of a healthy population of the same age. Today, the aim of this effective therapy should be to achieve a deep molecular response, because it significantly reduces the risk of adverse events: progression to accelerated phase / blast phase and the occurrence of mutations
- …
